Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 4/20 | 0.59 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.59 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.58 |
| ▸ | F2R | P25116 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.49 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.49 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11489205 | 0.86 | ITGB3 (0.60) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL29314560 | 0.85 | NPC1 (0.65) | NPC1ALDH1A1HSD11B1ATMTP53 | |
| SCHEMBL14303380 | 0.85 | ITGB3 (0.59) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL16083491 | 0.83 | ALDH1A1 (0.53) | GNAI3GNAO1GNAI1NPC1ITGB3 | |
| SCHEMBL8278505 | 0.83 | ITGB3 (0.61) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL3459102 | 0.81 | ITGB3 (0.55) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL4195892 | 0.81 | ITGB3 (0.55) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL23205790 | 0.81 | NPC1 (0.59) | GNAI3GNAO1GNAI1NPC1ALDH1A1 | |
| SCHEMBL13472173 | 0.80 | NPC1 (0.67) | GNAI3GNAO1GNAI1NPC1ITGB3 | |
| SCHEMBL26067161 | 0.79 | ITGB3 (0.54) | GNAI3GNAO1GNAI1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | GNAI3 938/4885GNAO1 3617/4885GNAI1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.